Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Bear Stearns Keeps 'Buy' on Serono

Bear Stearns maintains buy on Serono (SRA).

Analyst Tim Wilson says the approval is based on results of studies in patients with relapsing remitting multiple sclerosis (RRMS) PRISMS and EVIDENCE, with the latter being a head-to-head study against Biogen's Avonex. Rebif's approval breaks Avonex's U.S. Orphan Drug Status. Wilson says this is very good news for Serono. The company will will be aided by the strongest marketing argument any drug can have -- the FDA thinks Rebif is more efficacious than Avonex. To build his new model, Wilson says he must first hear what the company says about its rollout plan; he expects this will be detailed on a conference call on Mar. 11.

blog comments powered by Disqus